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Androgenetic alopecia (AGA), also known in women
as female pattern hair loss, is caused by androgens in
genetically susceptible women and men. The thinning
begins between ages 12 and 40 years, the inheritance
pattern is polygenic, and the incidence is the same as
in men. In susceptible hair follicles, dihydrotestosterone
binds to the androgen receptor, and the hormone-re-
ceptor complex activates the genes responsible for the
gradual transformation of large terminal follicles to
miniaturized follicles. Both young women and young
men with AGA have higher levels of 5a reductase and
androgen receptor in frontal hair follicles compared to
occipital follicles. At the same time, young women
have much higher levels of cytochrome p-450 aroma-
tase in frontal follicles than men who have minimal ar-
omatase, and women have even higher aromatase levels
in occipital follicles. The diagnosis of AGA in women is
supported by early age of onset, the pattern of increased
thinning over the frontal/parietal scalp with greater
density over the occipital scalp, retention of the frontal
hairline, and the presence of miniaturized hairs. Most
women with AGA have normal menses and pregnan-
cies. Extensive hormonal testing is usually not needed
unless symptoms and signs of androgen excess are pre-
sent such as hirsutism, severe unresponsive cystic acne,
virilization, or galactorrhea. Topical minoxidil solution
is the only drug available for promoting hair growth in
women with AGA. E⁄cacy has been shown in double-
blind studies using hair counts and hair weight. Key
words: female pattern hair loss/miniaturization/5a reductase/
aromatase/topical monoxidil. JID Symposium Proceedings
8:24 ^27, 2003
A
ndrogenetic alopecia (AGA), also known in women
as female pattern hair loss, is a common and distres-
sing cause of hair loss in women and men. In spite
of its prevalence, many clinicians and clinical inves-
tigators have di⁄culty making the diagnosis in
women. The hair thinning begins between the ages of 12 and
40 years in both sexes (Hamilton, 1951; Trancik et al, 2001;1) and
approximately half the population expresses this trait to some
degree before the age of 50 years (Venning and Dawber, 1988;
Olsen, 1994). Inheritance pattern of AGA is polygenic (complex
inheritance) and is inherited from either or both sides of the
family (Kuster and Happle, 1984; Sreekumar et al, 1999).
PATHOPHYSIOLOGY
AGA is induced by androgens in genetically susceptible women
and men. Hair follicles of women and men with AGA have in-
creased 5a-reductase activity and increased levels of dihydrotestos-
terone (DHT) (Schweikert and Wilson, 1974; Dallob et al, 1994;
Kaufman, 1996; Sawaya and Price, 1997). DHT, which is formed
by the peripheral conversion of testosterone by 5a-reductase, is
thought to be responsible for the characteristic miniaturization of
scalp hair follicles in AGA. In genetically susceptible
hair follicles, DHT binds to the androgen receptor, and the hor-
mone-receptor complex then activates the genes responsible for
the gradual transformation of large, terminal follicles to small,
miniaturized follicles (Price, 1975; Uno et al, 1985; Messenger,
1993; Kaufman, 1996). Over successive hair cycles in AGA, the
duration of anagen shortens and matrix size decreases, resulting
in smaller follicles that produce shorter, ¢ner, miniaturized hairs
that cover the scalp less and less well. These miniaturized hairs of
various lengths and diameters are the hallmark of AGA (Frieden
and Price, 1986;Whiting, 1993; Olsen, 1994). The number of folli-
cles per unit area, however, remains the same (Whiting, 1993).
In women with AGA, the extent of hair loss is generally less
than in men. It has been assumed that the hormonal basis for
AGA is similar in women as in men although earlier studies did
not include female subjects (Price, 1975; Frieden and Price, 1986).
In order to compare and clarify the underlying hormonal basis, a
study was conducted in 12 young women (ages 14^33) and 12
young men (ages 18^30) with AGA (Sawaya and Price, 1997). An-
drogen receptor, type I and type II 5a reductase, and cytochrome
p-450 aromatase, were measured in hair follicles from scalp biop-
sies of these young subjects. Both young women and young men
had higher levels of type I and type II 5a-reductase and androgen
receptors in frontal hair follicles compared to occipital hair folli-
cles; however, the levels in women were approximately half the
levels in men (Sawaya and Price, 1997). At the same time, young
women had much higher levels of cytochrome p-450 aromatase
in frontal follicles than men who had minimal aromatase, and
women had even higher aromatase levels in occipital follicles.
The di¡erences in aromatase, which is capable of converting tes-
tosterone to estradiol, are particularly notable. The ¢ndings of
this study suggest that the milder expression of AGA in women
may in part be the result of lower levels of 5a reductase and an-
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drogen receptors in frontal follicles of women compared to levels
in men; additionally, higher levels of aromatase in women may
result in increased local formation of estradiol from testosterone,
and less formation of 5a-reduced products such as DHT.
Although hair thinning in women with AGA may be di¡use,
nevertheless there is a pattern in women as there is in men, with
the frontal and parietal scalp generally showing the greatest thin-
ning and the occipital scalp showing the greatest hair density.
From a clinical perspective, hair follicles of the occipital scalp be-
have di¡erently from frontal and parietal scalp follicles: in AGA,
occipital follicles are typically spared by the hormonal in£uences;
and in alopecia areata, occipital follicles a¡ected by the ophiasis
pattern are typically more resistant to regrowth. These di¡erent
behaviors of occipital and frontal/parietal follicles may result
from the embryological derivation of the dermis in these two re-
gions. It is known from avian embryology that the dermis of the
frontal/parietal scalp is of neural crest origin, whereas the dermis
of the occipital scalp is of mesodermal origin (Ziller, 1996). Reg-
ulatory genes, growth factors, and cell^cell interactions may in-
£uence hair follicles di¡erently in the two regions based on their
dermal origin, and this may explain the patterning that is fre-
quently seen in scalp hair loss.
CLINICAL FEATURES OFAGA IN WOMEN
Women ¢rst notice hair thinning over the frontal area, and gra-
dually the scalp becomes more visible (Fig 1). Over time the
thinning, although it is often di¡use and may involve most of
the scalp, nevertheless is usually patterned with most marked
thinning over the frontal and parietal scalp, and with greater den-
sity over the occipital scalp.Women typically retain a rim of hair
along the frontal hairline (Figs 1, 2), even when the scalp is visi-
ble behind the hairline (Ludwig, 1977). Miniaturized hairs, the
shorter and ¢ner hairs of various lengths and diameters, are the
hallmark of AGA (Frieden and Price, 1986;Whiting, 1993) and re-
sult from the shortening of anagen phase and reduction in matrix
size. Increased spacing between hairs makes the central part ap-
pear wider over the frontal scalp compared to the occipital scalp.
Less commonly, hair density appears normal proximally, but
the hair no longer grows to its previous length, resulting in wispy
distal ends (Fig 3); in this case, the shortening of anagen pro-
gresses more rapidly than matrix reduction.The patient may note
that her ‘pony tail’ is smaller in girth and the hair is cut to shorter
lengths in order to give a fuller appearance. Rarely, advanced
thinning occurs with loss of the frontal hairline, but this is in-
variably associated with markedly elevated circulating androgens
(Ludwig, 1977).
Androgenetic alopecia in women is not usually accompanied
by increased shedding. However, in some instances, an episode
of telogen e¥uvium following childbirth, major illness or other
causes may uncover a latent predisposition to AGA. Sometimes
the number of hairs shed is misleading in women who seldom
comb their hair after shampooing, leave it to dry naturally; and
later when their hands ‘comb’ through the hair many loose hairs
appear on the ¢ngers.
LABORATORY EVALUATION
Extensive hormonal testing is usually not needed unless symp-
toms and signs of androgen excess are present. Most women with
AGA have normal menses and pregnancies.Women who require
endocrine evaluation are identi¢ed in the o⁄ce with careful in-
quiry regarding menses, history of infertility, and the presence
of hirsutism, severe unresponsive cystic acne, virilization, or ga-
lactorrhoea. If any one of these is present, laboratory measure-
ment of serum total or free tesosterone, dehydroepiandrosterone
sulfate and prolactin are indicated. Other common causes of hair
loss are ruled out by measurement of serum thyrotropin, iron
studies including serum iron and ferritin, complete blood count,
and RPR.
DIFFERENTIAL DIAGNOSIS
The diagnosis of AGA in women is supported by early age of
onset, the pattern of increased hair thinning over the frontal/par-
ietal scalp with greater hair density over the occipital scalp, reten-
tion of the frontal hairline, and the presence of miniaturized
hairs.
When these features are present, the diagnosis is not proble-
matic. However, AGA is common and other causes of hair loss
Figure1. AGA in a 29-year-old woman. Note thinning in the
frontal/parietal region and sparing of the frontal hairline.
Figure 2. Drawing of scalp regions. The frontal hairline refers to the
rim of hair at the anterior margin of the frontal scalp.
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may coexist and need to be recognized or excluded. Scalp biopsy
usually solves the di¡erential diagnosis. Biopsies are taken from
active, representative sites, and horizontal sectioning is preferred
because of the larger number of follicular structures that can be
studied (Headington, 1984;Whiting, 1990). In AGA, biopsy shows
increased numbers of miniaturized hairs, abundant and even en-
larged sebaceous glands, and minimal in£ammation though the
latter is controversial (Lattanand and Johnson, 1975; Whiting,
1998).
Chronic telogen e¥uvium (CTE) may present a di⁄cult dif-
ferential diagnosis even though the features of CTE seem dis-
tinct. In CTE, women in the fourth to sixth decade, with above
average hair density, describe sudden onset of marked shedding
from the entire scalp. Hair pull test may extract increased num-
bers of telogen hairs easily, yet scalp hair density appears normal
or minimally decreased even though the shedding may be pro-
longed. Miniaturized hairs are not seen. Horizontal sections of a
scalp biopsy distinguish CTE from AGA: the ratio of terminal
hairs to miniaturized hairs in CTE is 9 : 1, in AGA is 2 : 1, and
in a normal scalp is 7 : 1 (Whiting, 1996). Acute telogen e¥uvium
may occur in a woman with long-standing AGA or unmask la-
tent AGA. A careful history will usually identify the cause of
profuse hair shedding such as high fever, severe dietary protein
de¢ciency, or chronic blood loss as in women with prolonged
heavy menses. Relevant laboratory tests are noted above. Cate-
gories of drugs that may cause hair loss include anticancer drugs,
anticoagulants, anticonvulsants, antithyroid drugs, beta blockers,
tricyclic antidepressants, and progestins with androgenic e¡ects
(Mirmirani and Price, 2000). Both patchy and di¡use alopecia
areata may coexist with AGA and sometimes present a challen-
ging di¡erential which is resolved by a scalp biopsy showing a
peribulbar lymphocytic in¢ltrate around anagen hair bulbs. An
adult with loose anagen syndrome has a history of decreased hair
density since early childhood, and the pull test is strongly positive
(Price and Gummer, 1989). Low power microscopy of the easily
extracted hairs shows misshapen anagen bulbs, a ‘‘ru¥ed’’ cuticle
just distal to the bulb, and absent inner root sheath.
Figure 3. AGA showing the less common presentation of full prox-
imal hair density and wispy distal density; in these cases, the short-
ening of anagen progresses more rapidly than matrix reduction.
Figure 4. Mean change in hair weight in women using 2% topical
minoxidil solution twice daily for 32 weeks.
Figure 5. AGA in a 33-year-old woman before (top) and after (bot-
tom) applying 2% topical minoxidil solution for 12 months.
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MEDICALTREATMENT OFAGA IN WOMEN
Topical minoxidil solution is the only approved drug available
for promoting hair growth in women with AGA (Price, 1999).
E⁄cacy has been shown in double-blind, placebo-controlled stu-
dies using hair counts and hair weight as the primary end points
(Price, 1999). Minoxidil-treated women had signi¢cantly higher
hair counts and an increase in hair weight compared to women
who received placebo. A double-blind study of women ages
22^41years using 2% topical minoxidil solution showed a signif-
icant increase over placebo in mean change in hair weight at
16 weeks (Price and Menefee, 1990) (Fig 4). It should be noted
that clinical perception of improved scalp coverage may take
longer, up to 6^12 months, until hair length and mass are in-
creased su⁄ciently (Fig 5). Minoxidil solution must be applied
twice daily to a dry scalp.
Finasteride is a competitive inhibitor of type II 5a-reductase,
and is contraindicated in women who are or may become preg-
nant, because 5a-reductase inhibitors may cause abnormalities of
the external genitalia of a male fetus. Finasteride was not e¡ective
in postmenopausal women in a placebo-controlled study (Price
et al, 2000).
Women are devastated by their thinning hair (Cash et al, 1993),
and need thoughtful evaluation and management, as well as reas-
surance that they may safely use hair cosmetics to make their hair
appear fuller.
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